Skip to main content

Advertisement

SpringerLink
Log in

Active Antigen-specific Immunotherapy of Melanoma: from Basic Science to Clinical Investigation

  • Published:
World Journal of Surgery Aims and scope Submit manuscript

Abstract

Advanced-stage melanoma here dismal prognosis, and novel therapeutic approaches are urgently required. The possibility of taking advantage of the immune response of patients for its treatment has been an appealing concept for almost a century. Only during the last decade, however, has the molecular identification of tumor-associated antigens (TAAs) offered the possibility of vaccinating patients (e.g., active induction of TAA-specific immune responses). Active antigen-specific immunotherapy (AASIT) is currently being investigated in a number of clinical centers as a treatment option for advanced-stage melanoma. A large number of melanoma TAAs have been molecularly characterized and are being used in vaccination trials in various molecular forms and according to various immunization protocols. Here we provide a short overview on melanoma TAAs, the technologies currently in use to induce specific cytotoxic T-lymphocyte (CTL) responses in vivo, and their monitoring. We also propose a tentative AASIT agenda for the next few years, aiming at improving the capacity to induce and monitor TAA-specific immune responses and to verify their clinical effectiveness.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others

References

  1. P Bruggen ParticleVan der C Traversari P Chomez et al. (1991) ArticleTitleA gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma Science 254 1643–1647 Occurrence Handle1840703

    PubMed  Google Scholar 

  2. N Renkvist C Castelli PF Robbins et al. (2001) ArticleTitleA listing of human tumor antigens recognized by T cells Cancer Immunol. Immunother. 50 3–15 Occurrence Handle10.1007/s002620000169 Occurrence Handle11315507

    Article  PubMed  Google Scholar 

  3. AL Cox J Skipper Y Chen et al. (1994) ArticleTitleIdentification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines Science 264 716–719 Occurrence Handle7513441

    PubMed  Google Scholar 

  4. Y Kawakami S Eliyahu K Sakaguchi et al. (1994) ArticleTitleIdentification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes J. Exp. Med. 180 347–352 Occurrence Handle10.1084/jem.180.1.347 Occurrence Handle7516411

    Article  PubMed  Google Scholar 

  5. T Boon PG Coulie B Eynde ParticleVan den (1997) ArticleTitleTumor antigens recognized by T cells Immunol. Today 18 267–268 Occurrence Handle10.1016/S0167-5699(97)80020-5 Occurrence Handle9190110

    Article  PubMed  Google Scholar 

  6. MJ Scanlan AO Gure AA Jungbluth et al. (2002) ArticleTitleCancer/testis antigens: an expanding family of targets for cancer immunotherapy Immunol. Rev. 188 22–32 Occurrence Handle10.1034/j.1600-065X.2002.18803.x Occurrence Handle12445278

    Article  PubMed  Google Scholar 

  7. A Juretic GC Spagnoli E Schultzs-Thater et al. (2003) ArticleTitleCancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies Lancet Oncol. 4 104–109 Occurrence Handle10.1016/S1470-2045(03)00982-3 Occurrence Handle12573352

    Article  PubMed  Google Scholar 

  8. T Wölfel M Hauer J Schneider et al. (1995) ArticleTitleA p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma Science 269 1281–1284 Occurrence Handle7652577

    PubMed  Google Scholar 

  9. PF Robbins M EI-Gamil YF Li et al. (1997) ArticleTitleThe intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes J. Immunol. 159 303–308 Occurrence Handle9200467

    PubMed  Google Scholar 

  10. LA Koutsky KA Ault C Wheeler et al. (2002) ArticleTitleA controlled trial of a human papillomavirus type 16 vaccine N. Engl. J. Med. 347 1645–1651 Occurrence Handle10.1056/NEJMoa020586 Occurrence Handle12444178

    Article  PubMed  Google Scholar 

  11. RM Zinkernagel (2002) ArticleTitleOn differences between immunity and immunological memory Curr. Opin. Immunol. 14 523–536 Occurrence Handle10.1016/S0952-7915(02)00367-9 Occurrence Handle12088689

    Article  PubMed  Google Scholar 

  12. D Wodarz (2003) ArticleTitleHepatitis C virus dynamics and pathology: the role of CTL and antibody responses J. Gen. Virol. 84 1743–1750 Occurrence Handle10.1099/vir.0.19118-0 Occurrence Handle12810868

    Article  PubMed  Google Scholar 

  13. DT O’Hagan NM Valiante (2003) ArticleTitleRecent advances in the discovery and delivery of vaccine adjuvants Nat. Rev. Drug Discov. 2 727–735 Occurrence Handle10.1038/nrd1176 Occurrence Handle12951579

    Article  PubMed  Google Scholar 

  14. R Schumacher M Adamina R Zurbriggen et al. (2004) ArticleTitleInfluenza virosomes enhance class I restricted CTL induction through CD4 T cell activation Vaccine 22 714–723 Occurrence Handle10.1016/j.vaccine.2003.08.019 Occurrence Handle14741164

    Article  PubMed  Google Scholar 

  15. M Marchand N Baren Particlevan P Weynants et al. (1999) ArticleTitleTumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1 Int. J. Cancer 80 219–230 Occurrence Handle10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S Occurrence Handle9935203

    Article  PubMed  Google Scholar 

  16. E Jager M Ringhoffer HP Dienes et al. (1996) ArticleTitleGranulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo Int. J. Cancer 67 54–62 Occurrence Handle10.1002/(SICI)1097-0215(19960703)67:1<54::AID-IJC11>3.0.CO;2-C Occurrence Handle8690525

    Article  PubMed  Google Scholar 

  17. SA Rosenberg JC Yang DJ Schwatrzentruber et al. (1998) ArticleTitleImmunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nat. Med. 4 321–327 Occurrence Handle10.1038/nm0398-321 Occurrence Handle9500606

    Article  PubMed  Google Scholar 

  18. AC Peterson H Harlin TF Gajewski (2003) ArticleTitleImmunization with Melan-A peptide–pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma J. Clin. Oncol. 21 2342–2348 Occurrence Handle10.1200/JCO.2003.12.144 Occurrence Handle12805336

    Article  PubMed  Google Scholar 

  19. J Weber VK Sondak R Scotland et al. (2003) ArticleTitleGranulocyte-macrophage colony-stimulating factor added to a multipeptide vaccine for resected stage II melanoma Cancer 97 186–200 Occurrence Handle10.1002/cncr.11045 Occurrence Handle12491520

    Article  PubMed  Google Scholar 

  20. F Wang E Bade C Kuniyoshi et al. (1999) ArticleTitlePhase I trial of a MART-1 peptide vaccine with incomplete Freund’s adjuvant for resected high risk melanoma Clin. Cancer Res. 5 2756–2765 Occurrence Handle10537339

    PubMed  Google Scholar 

  21. SG Schaed VM Klimek KS Panageas et al. (2002) ArticleTitleT-cell responses against tyrosinase 368-376(3700) peptide in HLA-A0201+ melanoma patients: randomized trial comparing incomplete Freund’s adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants Clin. Cancer Res. 8 967–972 Occurrence Handle12006508

    PubMed  Google Scholar 

  22. FO Nestle S Alijagic M Gilliet et al. (1998) ArticleTitleVaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells Nat. Med. 4 328–332 Occurrence Handle10.1038/nm0398-328 Occurrence Handle9500607

    Article  PubMed  Google Scholar 

  23. A Mackensen B Herbst JL Chen et al. (2000) ArticleTitlePhase I study in melanoma patients of a vaccine with peptide pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells Int. J. Cancer 86 385–392 Occurrence Handle10.1002/(SICI)1097-0215(20000501)86:3<385::AID-IJC13>3.0.CO;2-T Occurrence Handle10760827

    Article  PubMed  Google Scholar 

  24. J Banchereau AK Palucka M Dhodapkar et al. (2001) ArticleTitleImmune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine Cancer Res. 61 6451–6458 Occurrence Handle11522640

    PubMed  Google Scholar 

  25. B Thurner I Haendle C Roder et al. (1999) ArticleTitleVaccination with mage-3A1 peptide-pulsed mature, monocyte derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma J. Exp. Med. 190 1669–1678 Occurrence Handle10.1084/jem.190.11.1669 Occurrence Handle10587357

    Article  PubMed  Google Scholar 

  26. CL Slingluff GR Petroni GV Yamshchikov et al. (2003) ArticleTitleClinical and immunological results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells J. Clin. Oncol. 21 4016–4026 Occurrence Handle10.1200/JCO.2003.10.005 Occurrence Handle14581425

    Article  PubMed  Google Scholar 

  27. I Bedrosian R Mick S Xu et al. (2003) ArticleTitleIntranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients J. Clin. Oncol. 21 3826–3835 Occurrence Handle10.1200/JCO.2003.04.042 Occurrence Handle14551301

    Article  PubMed  Google Scholar 

  28. SA Rosenberg Y Zhai JC Yang et al. (1998) ArticleTitleImmunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens J. Natl. Cancer Inst. 90 1894–1900 Occurrence Handle10.1093/jnci/90.24.1894 Occurrence Handle9862627

    Article  PubMed  Google Scholar 

  29. D Oertli WR Marti P Zajac et al. (2002) ArticleTitleRapid induction of specific cytotoxic T lymphocytes against melanoma associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo Hum. Gene Ther. 13 569–575 Occurrence Handle10.1089/10430340252809856 Occurrence Handle11874634

    Article  PubMed  Google Scholar 

  30. P Zajac D Oertli W Marti et al. (2003) ArticleTitlePhase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients Hum. Gene Ther. 14 1497–1510 Occurrence Handle10.1089/104303403322495016 Occurrence Handle14577912

    Article  PubMed  Google Scholar 

  31. C Yee JA Thompson D Byrd et al. (2002) ArticleTitleAdoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells Proc. Natl. Acad. Sci. USA. 99 16168–16173 Occurrence Handle10.1073/pnas.242600099 Occurrence Handle12427970

    Article  PubMed  Google Scholar 

  32. N Meidenbauer J Marienhagen M Laumer et al. (2003) ArticleTitleSurvival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients J. Immunol. 170 2161–2169 Occurrence Handle12574389

    PubMed  Google Scholar 

  33. ME Dudley JR Wunderlich PF Robbins et al. (2002) ArticleTitleCancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science 298 850–854 Occurrence Handle10.1126/science.1076514 Occurrence Handle12242449

    Article  PubMed  Google Scholar 

  34. E. Celis (2002) ArticleTitleGetting peptide vaccines to work: just a matter of quality control? J Clin. Invest. 110 1765–1768 Occurrence Handle10.1172/JCI200217405

    Article  Google Scholar 

  35. G Parmiani C Castelli P Dalerba et al. (2002) ArticleTitleCancer immunotherapy with peptide based vaccines: what have we achieved ? Where are we going? J Natl. Cancer Inst. 94 805–818

    Google Scholar 

  36. AA Amoscato DA Prenowitz MT Lotze (1998) ArticleTitleRapid extracellular degradation of synthetic class I peptides by human dendritic cells J. Immunol. 161 4023–4032 Occurrence Handle9780172

    PubMed  Google Scholar 

  37. F Albo A Cavazza B Giardina et al. (2004) ArticleTitleDegradation of the tumor antigen epitope gp100 (280-288) by fibroblast-associated enzymes abolishes specific imrnunorecognition Biochim. Biophys. Acta 167 59–69

    Google Scholar 

  38. JS Blanchet D Valmori I Dufau et al. (2001) ArticleTitleA new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implications for molecular anti-malanoma immunotherapy J. Immunol. 167 5852–5861 Occurrence Handle11698460

    PubMed  Google Scholar 

  39. JW Smith EB Walker BA Fox et al. (2003) ArticleTitleAdjuvant immunization of HLA-A2-positive melanoma patients with modified gp100 peptide induces peptide-specific CD8+ T-cell responses J. Clin. Oncol. 21 1562–1573 Occurrence Handle10.1200/JCO.2003.09.020 Occurrence Handle12697882

    Article  PubMed  Google Scholar 

  40. CG Figdor IJ Vries Particlede WJ Lesterhuis et al. (2004) ArticleTitleDendritic cell immunotherapy: mapping the way Nat. Med. 10 475–480 Occurrence Handle10.1038/nm1039 Occurrence Handle15122249

    Article  PubMed  Google Scholar 

  41. A Mackensen R Drager M Schlesier et al. (2000) ArticleTitlePresence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells Cancer Immunol. Immunother. 49 152–156 Occurrence Handle10.1007/s002620050614 Occurrence Handle10881694

    Article  PubMed  Google Scholar 

  42. J Schneider SC Gilbert CM Hannan et al. (1999) ArticleTitleInduction of CD8+ T cells using heterologous prime-boost immunisation strategies Immunol. Rev. 170 29–38 Occurrence Handle10566139

    PubMed  Google Scholar 

  43. AF Ochsenbein S Sierro B Odermatt et al. (2001) ArticleTitleRoles of tumour localization, second signals and cross-priming in cytotoxic T-cell induction Nature 411 1058–1064 Occurrence Handle11429607

    PubMed  Google Scholar 

  44. AW Goldrath PV Sivakumar M Glaccum et al. (2002) ArticleTitleCytokine requirements for acute and basal homeostatic proliferation of naive and memory CD8+ T cells J. Exp. Med. 195 1515–1522 Occurrence Handle10.1084/jem.20020033 Occurrence Handle12070279

    Article  PubMed  Google Scholar 

  45. JT Tan B Ernst WC Kieper et al. (2002) ArticleTitleInterleukin (IL)-15, IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells J. Exp. Med. 195 1523–1532 Occurrence Handle10.1084/jem.20020066 Occurrence Handle12070280

    Article  PubMed  Google Scholar 

  46. A Cassone P Mastrantonio CM Ausiello (2000) ArticleTitleAre only antibody levels involved in the protection against pertussis in acellular pertussis vaccine recipients? Infect. Dis. 186 351–360

    Google Scholar 

  47. P Romero JC Cerottini DE Speiser (2004) ArticleTitleMonitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination Cancer Immunol. Immunother. 53 249–255 Occurrence Handle10.1007/s00262-003-0473-9 Occurrence Handle14704832

    Article  PubMed  Google Scholar 

  48. JD Altman PA Moss PJ Goulder et al. (1996) ArticleTitlePhenotypic analysis of antigen-specific T lymphocytes Science 274 94–96 Occurrence Handle10.1126/science.274.5284.94 Occurrence Handle8810254

    Article  PubMed  Google Scholar 

  49. W Herr B Linn N Leister et al. (1997) ArticleTitleThe use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens J. Immunol. Methods 203 141–152 Occurrence Handle10.1016/S0022-1759(97)00019-7 Occurrence Handle9149807

    Article  PubMed  Google Scholar 

  50. MJ Pittet A Zippelius DE Speiser et al. (2001) ArticleTitleEx vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases J. Immunol. 166 7634–7640 Occurrence Handle11390521

    PubMed  Google Scholar 

  51. US Kammula KH Lee AI Riker et al. (1999) ArticleTitleFunctional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens J. Immunol. 163 6867–6875 Occurrence Handle10586088

    PubMed  Google Scholar 

  52. M Provenzano JB Lim S Mocellin et al. (2004) ArticleTitleThe matrix protein pp65(341–350): a peptide that induces ex vivo stimulation and in vitro expansion of CMV-specific CD8+ T cells in subjects bearing either HLA-A 2402 or A 0101 allele Transfusion 43 1567–1574 Occurrence Handle10.1046/j.1537-2995.2003.00564.x

    Article  Google Scholar 

  53. MC Panelli A Riker U Kammula et al. (2000) ArticleTitleExpansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases J. Immunol. 164 495–504 Occurrence Handle10605047

    PubMed  Google Scholar 

  54. C Yee JA Thompson P Roche et al. (2000) ArticleTitleMelanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell mediated vitiligo J. Exp. Med. 192 1637–1644 Occurrence Handle10.1084/jem.192.11.1637 Occurrence Handle11104805

    Article  PubMed  Google Scholar 

  55. GQ Phan JC Yang RM Sherry et al. (2003) ArticleTitleCancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma Proc. Natl. Acad. Sci. U.S.A. 100 8372–8377 Occurrence Handle10.1073/pnas.1533209100 Occurrence Handle12826605

    Article  PubMed  Google Scholar 

  56. CR Alving (2002) ArticleTitleDesign and selection of vaccine adjuvants: animal models and human trials Vaccine 20 S56–S64 Occurrence Handle10.1016/S0264-410X(02)00174-3 Occurrence Handle12184368

    Article  PubMed  Google Scholar 

  57. MB Atkins MT Lotze JP Dutcher et al. (1999) ArticleTitleHigh-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 J. Clin. Oncol. 17 2105–2116 Occurrence Handle10561265

    PubMed  Google Scholar 

  58. JE Portielje JW Gratama HH Ojik Particlevan et al. (2003) ArticleTitleIL-12: a promising adjuvant for cancer vaccination Cancer Immunol. Immunother. 52 133–144 Occurrence Handle12649742

    PubMed  Google Scholar 

  59. T Vial J Descotes (1995) ArticleTitleClinical toxicity of cytokines used as haemopoietic growth factors Drug. Saf. 13 371–406 Occurrence Handle8652081

    PubMed  Google Scholar 

  60. DG McNeel K Schiffman ML Disis (1999) ArticleTitleImmunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and a humoral response to recombinant recombinant human granulocyte-macrophage colony-stimulating factor Blood 93 2653–2659 Occurrence Handle10194445

    PubMed  Google Scholar 

  61. PJ Hurwitz (1991) ArticleTitleSpontaneous regression of metastatic melanoma Ann. Plast. Surg. 26 403–406 Occurrence Handle1872546

    PubMed  Google Scholar 

  62. MF Avril P Charpentier A Margulis et al. (1992) ArticleTitleRegression of primary melanoma with metastases Cancer 69 1377–1381 Occurrence Handle1540876

    PubMed  Google Scholar 

  63. JA Sosman AT Weeraratna VK Sondak (2004) ArticleTitleWhen will melanoma vaccines be proven effective? J. Clin. Oncol. 22 387–389 Occurrence Handle10.1200/JCO.2004.11.950 Occurrence Handle14691126

    Article  PubMed  Google Scholar 

  64. FM Marincola EM Jaffee DJ Hicklin et al. (2000) ArticleTitleEscape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance Adv. Immunol. 74 181–273 Occurrence Handle10605607

    PubMed  Google Scholar 

  65. KS Schluns L Lefrancois (2003) ArticleTitleCytokine control of memory T-cell development and survival Nat. Rev. Immunol. 3 269–279 Occurrence Handle10.1038/nri1052 Occurrence Handle12669018

    Article  PubMed  Google Scholar 

  66. RM Zinkernagel (2001) ArticleTitle Immunity against solid tumors? Int. J. Cancer 93 1–5 Occurrence Handle10.1002/ijc.1305 Occurrence Handle11391613

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was partially funded by grants from the Swiss Bridge Foundation and by the Swiss Science Foundation.

Author information

Authors and Affiliations

  1. Institut für chirurgische Forschung und Spitalmanagement and Department of Surgery, University of Basel, c/o ZLF, 20 Hebelstrasse, 4031, Basel, Switzerland

    Giulio C. Spagnoli M.D., Michel Adamina M.D., Martin Bolli M.D., Walter P. Weber M.D., Paul Zajac Ph.D., Walter Marti M.D., Daniel Oertli M.D., Michael Heberer M.D. & Felix Harder M.D.

Authors
  1. Giulio C. Spagnoli M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michel Adamina M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin Bolli M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Walter P. Weber M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paul Zajac Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Walter Marti M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Daniel Oertli M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Michael Heberer M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Felix Harder M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giulio C. Spagnoli M.D..

Additional information

This work was partially funded by grants from the Swiss Bridge Foundation and by the Swiss Science Foundation.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Spagnoli, G.C., Adamina, M., Bolli, M. et al. Active Antigen-specific Immunotherapy of Melanoma: from Basic Science to Clinical Investigation. World J. Surg. 29, 692–699 (2005). https://doi.org/10.1007/s00268-005-7762-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-005-7762-8

Keywords

Search

Navigation